TriSalus Life Sciences, Inc.

TriSalus Life Sciences, Inc. is a clinical-stage oncology company that completed its de-SPAC merger with MedTech Acquisition Corp (Nasdaq: MTAC), a blank-check vehicle sponsored by MedTech Acquisition Holdings LLC that priced its IPO in 2021 targeting the healthcare and medical technology sector. The business combination closed in 2022, after which the combined company began trading on Nasdaq under the ticker TLSI. TriSalus focuses on pressure-enabled regional drug delivery for hepatic and pancreatic cancers. The Form 10-K filed March 22, 2023 serves as the company's first full annual disclosure as a post-merger public entity. Sign up at SpacDesk for complete filing history, deal timelines, and sponsor data on this and hundreds of other SPAC transactions.